Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of h20.19 CAR T Cells in Relapsed/Refractory B Cell Malignancies
NCT07335328Phase 1Not yet recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Nov 2026
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of h20.19 CAR T cells in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and 2 more (3 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
h20.19 CAR T cells
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07335328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335328.